North American Prodromal Synucleinopathy Consortium
This study will enroll participants with idiopathic rapid eye movement (REM) sleep behavior disorder (RBD), for the purpose of preparing for a clinical trial of neuroprotective treatments against synucleinopathies.
Stanford is currently accepting patients for this trial.
Washington University School of Medicine
Collaborator: Mayo Clinic
- Idiopathic REM sleep behavior disorder
- REM sleep behavior disorder secondary to another cause (ex: narcolepsy, dementia,
Parkinson's Disease, etc)
- Other neurological disorder
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study